GLP-1 Research
New DXA and MRI data from major tirzepatide trials reveal how the drug reshapes body composition — and…
GLP-1 medications can drive significant muscle loss in the first year — here's what the research shows and…
Semaglutide is sold under three brand names — Ozempic, Wegovy, and Rybelsus — each approved for different clinical…
Emerging research suggests GLP-1 receptor agonists not only avoid increasing depression risk but may offer direct neuropsychiatric benefits…
Stopping Ozempic triggers powerful hormonal rebound mechanisms that drive weight regain — here's what the research shows and…
Tirzepatide has produced up to 20% weight loss and a 93% reduction in diabetes progression in major clinical…
Tirzepatide has now outperformed semaglutide head-to-head and cut diabetes progression risk by 93% in three-year trials — here's…
Progressive overload—gradually increasing training demands—is the science-backed foundation of muscle and strength gains. Here's how beginners should implement…
Semaglutide causes mostly mild-to-moderate GI side effects, but research reveals important safety considerations around gallstones, pancreatic monitoring, and…
New research reveals how GLP-1 medications affect the brain's reward pathways—and what it teaches us about cravings, food…